Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-05-26 5:04 pm Purchase | 2026-05-21 | 13D | KINIKSA PHARMACEUTICALS INTL P KNSA | BAKER BROS. ADVISORS LP | 3,253,341 7.000% | 102,312 (+3.25%) | Filing History |
| 2026-05-06 11:23 am Purchase | 2026-03-31 | 13G | KINIKSA PHARMACEUTICALS INTL P KNSA | FMR LLC | 6,787,700 14.800% | 1,933,346 (+39.83%) | Filing History |
| 2026-03-27 10:17 am Sale | 2026-03-13 | 13G | KINIKSA PHARMACEUTICALS INTL P KNSA | VANGUARD GROUP INC | 0 0.000% | -3,063,135 (Position Closed) | Filing History |
| 2026-03-06 10:05 am Purchase | 2026-02-27 | 13G | KINIKSA PHARMACEUTICALS INTL P KNSA | FMR LLC | 4,854,354 10.600% | 4,854,354 (New Position) | Filing History |
| 2026-02-13 4:07 pm Sale | 2025-12-31 | 13G | KINIKSA PHARMACEUTICALS INTL P KNSA | Rubric Capital Management LP | 3,328,653 7.370% | -581,153 (-14.86%) | Filing History |
| 2025-10-31 11:04 am Purchase | 2025-09-30 | 13G | KINIKSA PHARMACEUTICALS INTL P KNSA | VANGUARD GROUP INC | 3,063,135 7.040% | 97,836 (+3.30%) | Filing History |
| 2025-07-17 7:44 pm Sale | 2025-06-30 | 13G | KINIKSA PHARMACEUTICALS INTL P KNSA | BlackRock Inc. BLK | 418,151 1.000% | -1,843,915 (-81.51%) | Filing History |
| 2025-07-09 4:06 pm Purchase | 2025-06-30 | 13G | KINIKSA PHARMACEUTICALS INTL P KNSA | Rubric Capital Management LP | 3,909,806 9.240% | 526,567 (+15.56%) | Filing History |
| 2025-05-14 4:04 pm Purchase | 2025-03-31 | 13G | KINIKSA PHARMACEUTICALS INTL P KNSA | Rubric Capital Management LP | 3,383,239 8.050% | 964,136 (+39.86%) | Filing History |
| 2025-04-23 7:47 pm Sale | 2025-03-31 | 13G | KINIKSA PHARMACEUTICALS INTL P KNSA | BlackRock Inc. BLK | 2,262,066 5.400% | -1,553,590 (-40.72%) | Filing History |
| 2025-04-04 6:57 pm Purchase | 2025-03-28 | 13G | KINIKSA PHARMACEUTICALS INTL P KNSA | TANG CAPITAL MANAGEMENT LLC | 2,178,609 5.200% | 2,178,609 (New Position) | Filing History |
| 2025-02-14 3:45 pm Sale | 2024-12-31 | 13G | KINIKSA PHARMACEUTICALS INTL P KNSA | Fairmount Funds Management LLC | 0 0.000% | -3,204,841 (Position Closed) | Filing History |
| 2024-11-14 4:32 pm Sale | 2024-09-30 | 13G | KINIKSA PHARMACEUTICALS INTL P KNSA | HHLR ADVISORS LTD. | 1,582,635 3.900% | -2,296,791 (-59.20%) | Filing History |
| 2024-11-14 4:15 pm Purchase | 2024-09-30 | 13G | KINIKSA PHARMACEUTICALS INTL P KNSA | Fairmount Funds Management LLC | 3,204,841 7.900% | 321,620 (+11.15%) | Filing History |
| 2024-11-13 4:30 pm Sale | 2024-09-30 | 13G | KINIKSA PHARMACEUTICALS INTL P KNSA | Rubric Capital Management LP | 2,419,103 5.960% | -488,398 (-16.80%) | Filing History |
| 2024-11-08 5:31 pm Unchanged | 2024-09-30 | 13G | KINIKSA PHARMACEUTICALS INTL P KNSA | BlackRock Inc. BLK | 3,815,656 9.400% | 0 (Unchanged) | Filing |
| 2024-10-21 4:11 pm Sale | 2024-09-30 | 13G | KINIKSA PHARMACEUTICALS INTL P KNSA | BlackRock Inc. BLK | 3,815,656 9.400% | -376,790 (-8.99%) | Filing |
| 2024-10-08 5:29 pm Purchase | 2024-10-04 | 13D | KINIKSA PHARMACEUTICALS INTL P KNSA | BAKER BROS. ADVISORS LP | 3,151,029 7.700% | 247,999 (+8.54%) | Filing History |
| 2024-04-05 12:21 pm Purchase | 2024-03-31 | 13G | KINIKSA PHARMACEUTICALS INTL P KNSA | BlackRock Inc. BLK | 4,192,446 10.500% | 1,011,858 (+31.81%) | Filing |
| 2024-02-14 4:39 pm Purchase | 2023-12-31 | 13G | KINIKSA PHARMACEUTICALS INTL P KNSA | HHLR ADVISORS LTD. | 3,879,426 9.900% | 338,125 (+9.55%) | Filing History |